"The acquisition will enable us to step up our strategic initiative in the CRAMS segment," Lupin Chairman Desh Bandhu Gupta said.
Leading pharmaceutical company Lupin Ltd on Wednesday said it was looking at acquiring companies and brands in a bid to strengthen its paediatric business in the US market.
.jpg)
The company's US subsidiary, Lupin Pharmaceuticals Inc has launched its Ciprofloxacin for oral suspension in the US market in the strengths of 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL), Lupin said in a statement.
Pharma company Lupin Ltd will discontinue its Rofecoxib formulation, a painkiller, following the government ban on the drug after evidence showed its prolonged use led to increased risk of heart attacks.
Quarterly earnings, macroeconomic data announcements and global trends will drive the Indian stock markets in a holiday-shortened week, analysts said. Stock markets would remain closed on Wednesday for the Guru Nanak Gurpurab holiday.
Lupin Ltd received marketing approval from the US Food and Drug Administration to market its Cefixime oral suspension drug in the US, Ranbaxy Laboratories has received approval to market two strengths of Cefprozil tablets and Cefprozil powder.
Lupin Ltd said it currently has no plans to raise money from any investor.
In another development, leading Japanese drug maker Takeda Pharmaceutical sued Ahmedabad-based Torrent Pharma in the US for infringing seven patents covering its flagship diabetes drug, Actos. Oracea (doxycycline) is the only US Food and Drug Administration approved oral drug to treat rosacea -- a skin disorder in the face with inflammation, skin redness and spider veins.
Cephalon, a US-based drug maker, has filed a lawsuit against Lupin Ltd and its US subsidiary Lupin Pharmaceuticals for challenging the patents on its sleep disorder drug Nuvigil.
Pfizer, the world's largest pharmaceutical company, has filed patent infringement suits against Sun Pharma, Wockhardt Ltd and Lupin Ltd to prevent these companies from securing marketing approvals for the generic equivalents of its high-selling neuropathic pain management drug Lyrica in the United States.
Pharmaceutical company Lupin Ltd and US-based Cornerstone BioPharma Inc have entered into a $10.5 million licensing agreement
Lupin Ltd commissioned its facility at Mandideep near Bhopal, Madhya Pradesh, to manufacture Lisinopril, an active pharmaceutical ingredient in the cardiovascutar segment with a capacity of 12MT per annum.
Drug maker Lupin Ltd on Thursday said it would acquire 51 per cent stake in Belgium-based Artifex Finance CVA for an undisclosed sum.
Lupin Ltd will set up a Rs 100-million plant for manufacturing Lovastatin, a cholesterol lowering active pharmaceutical ingredient, at the company's facilities in Tarapur, Maharashtra.
Lupin Pharmaceuticals Inc, a wholly owned subsidiary of Mumbai-based Lupin Ltd, has forayed into the US pediatric segment by inking an agreement with Allergan Inc to promote 'Zymar' in that country.
Lupin Ltd received US Food & Drug Administration's approval for its abbreviated new drug application for Cefuroxime Axetil tablets.
The company has received a tentative approval for the company's abbreviated new drug application for Eszopiclone tablets from the US Food and Drug Administration, Lupin said in a filing to the Bombay Stock Exchange.
The US Court of Appeals for the Federal Circuit has ruled in the company's favour regarding its appeal of a previous judgement by a lower court for Bayer AG's Yaz oral contraceptive product.
The company has received final approval for its supplemental New Drug Application (sNDA) for Antara (Fenofibrate) capsules in 30 mg and 90 mg strengths from the United States Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
Lupin Ltd, one of the top five domestic pharmaceutical companies, plans to revamp its drug research programme and foray into novel biotech and reverse engineering of biotech drugs (or biosimilars).
Lupin Ltd is considering to set up its own marketing force in the United States even as the pharma major is to create a global advisory board as part of its corporate governance initiative.\n\n\n\n
Lupin Ltd on Thursday said it has received USFDA approval for its Abbreviated New Drug Application for multiple strengths of antibiotic Cephalexin capsules.
Sun Pharmaceutical Industries and Lupin Ltd will soon add another generic drug each to their US product basket. The companies received approvals from the US drug regulator to market generic equivalent of Pfizer's Dilantin Kapseals and Abbot's Mavik r
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally.
Lupin Ltd has posted a net profit of Rs 226.60 million for the quarter ended December 31, 2002 as compared to a net profit of Rs 184.70 million in the quarter ended December 31,2001.
The recent recalls come amid increased FDA scrutiny of medicines produced in India.
Lupin Ltd has reported a 38.36 per cent rise in net profit at Rs 28.06 crore (Rs 280.6 million) for the first quarter ended June 30, 2003 as against Rs 20.28 crore (Rs 202.8 million) for the corresponding quarter last fiscal.
The company has received final approval from the US Food and Drug Administration for its Abacavir Sulfate Lamivudine, and Zidovudine Tablets, Lupin Ltd said in a statement.
The company said it has acquired 100 per cent equity stake in Laboratorios Grin, Mexico.
The domestic stock market this week would monitor the geopolitical developments after India and Pakistan reached an understanding to stop military actions, analysts said. Moreover, macroeconomic data announcements, Q4 earnings, trading activity of foreign investors and global market trends are also likely to influence sentiments, traders said.
The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India.
This helps consumers check the authenticity of drugs simply by sending SMSes.
The new drugs to come under price control include commonly-used antibiotics and painkillers
Indian government has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics.
The Melbourne-headquartered Generic Health markets generic prescription and over-the-counter products in the Australian market, in a partnership model with established global generic drug makers. The company sells approximately $500 million (nearly Rs 2,150 crore) worth of drugs in Australia, which has Rs 11,300 crore (A$3 billion) worth generics market. The total drug market in Australia is worth A$10 billion (Rs37,800 crore).
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
A six-member jury headed by former Securities and Exchange Board of India chairman M Damodaran will declare the winner of the award for 2009 on February 16 in Mumbai.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances